CN104387333B - 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1,2,4‑三唑‑3‑基硫基)乙酸钠的晶型及其制备方法 - Google Patents
2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1,2,4‑三唑‑3‑基硫基)乙酸钠的晶型及其制备方法 Download PDFInfo
- Publication number
- CN104387333B CN104387333B CN201410659325.0A CN201410659325A CN104387333B CN 104387333 B CN104387333 B CN 104387333B CN 201410659325 A CN201410659325 A CN 201410659325A CN 104387333 B CN104387333 B CN 104387333B
- Authority
- CN
- China
- Prior art keywords
- crystal form
- bases
- bromo
- cyclopropyl naphthalene
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
2theta | d间隔 | 相对强度% |
4.58 | 19.28 | 37.67 |
9.19 | 9.62 | 100.00 |
10.27 | 8.61 | 27.38 |
12.87 | 6.88 | 32.49 |
13.82 | 6.41 | 19.81 |
14.73 | 6.01 | 19.91 |
17.76 | 4.99 | 26.56 |
18.45 | 4.81 | 44.37 |
19.93 | 4.46 | 36.12 |
21.84 | 4.07 | 29.53 |
22.52 | 3.95 | 25.66 |
23.13 | 3.84 | 44.57 |
23.63 | 3.77 | 37.39 |
25.20 | 3.53 | 30.66 |
26.01 | 3.43 | 25.46 |
26.74 | 3.33 | 26.26 |
27.87 | 3.20 | 24.10 |
28.48 | 3.13 | 26.82 |
28.89 | 3.09 | 22.46 |
29.94 | 2.98 | 31.91 |
31.34 | 2.85 | 10.72 |
35.46 | 2.53 | 14.25 |
36.25 | 2.48 | 10.11 |
38.90 | 2.32 | 10.29 |
2theta | d间隔 | 相对强度% |
4.69 | 18.84 | 83.23 |
7.32 | 12.07 | 58.33 |
9.31 | 9.50 | 77.56 |
10.37 | 8.53 | 100 |
12.60 | 7.02 | 33.24 |
12.97 | 6.83 | 76.17 |
13.78 | 6.43 | 16.87 |
14.82 | 5.98 | 24.33 |
15.64 | 5.67 | 24.54 |
16.12 | 5.50 | 26.08 |
17.82 | 4.98 | 46.87 |
18.19 | 4.88 | 25.02 |
18.61 | 4.77 | 19.16 |
20.05 | 4.43 | 28.19 |
20.72 | 4.29 | 6.26 |
21.94 | 4.05 | 40.5 |
22.52 | 3.95 | 39.13 |
22.77 | 3.91 | 33.29 |
23.71 | 3.75 | 65.7 |
24.34 | 3.66 | 19.35 |
25.26 | 3.53 | 58.83 |
26.05 | 3.42 | 33.47 |
26.57 | 3.35 | 11.78 |
27.95 | 3.19 | 14.21 |
28.60 | 3.12 | 34.66 |
29.01 | 3.08 | 31.88 |
29.98 | 2.98 | 24.23 |
30.57 | 2.92 | 19.26 |
31.32 | 2.86 | 20.55 |
32.57 | 2.75 | 11.2 |
35.50 | 2.53 | 12.57 |
38.77 | 2.32 | 4.68 |
2theta | d间隔 | 相对强度% |
4.50 | 19.63 | 18.23 |
9.04 | 9.78 | 100 |
13.65 | 6.49 | 9.24 |
18.23 | 4.87 | 49.17 |
22.86 | 3.89 | 31.57 |
27.51 | 3.24 | 10.07 |
29.45 | 3.03 | 4.08 |
Claims (3)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410659325.0A CN104387333B (zh) | 2013-12-02 | 2014-11-19 | 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1,2,4‑三唑‑3‑基硫基)乙酸钠的晶型及其制备方法 |
CN201710060519.2A CN106883190A (zh) | 2013-12-02 | 2014-11-19 | 雷西纳得的钠盐的晶型及其制备方法 |
JP2016554929A JP6470761B2 (ja) | 2013-11-22 | 2014-11-20 | レシヌラドおよびそのナトリウム塩の結晶形態 |
EP14863925.5A EP3071554B1 (en) | 2013-11-22 | 2014-11-20 | Crystalline forms of lesinurad |
ES14863925T ES2704198T3 (es) | 2013-11-22 | 2014-11-20 | Formas cristalinas de lesinurad |
CA2931430A CA2931430A1 (en) | 2013-11-22 | 2014-11-20 | Crystalline forms of lesinurad and its sodium salt |
AU2014351486A AU2014351486C1 (en) | 2013-11-22 | 2014-11-20 | Crystalline forms of lesinurad and its sodium salt |
PCT/IB2014/003077 WO2015075561A2 (en) | 2013-11-22 | 2014-11-20 | Crystalline forms of lesinurad and its sodium salt |
US15/038,470 US10351536B2 (en) | 2013-11-22 | 2014-11-20 | Crystalline forms of lesinurad and its sodium salt |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013106333545 | 2013-12-02 | ||
CN201310633354.5A CN103613552A (zh) | 2013-12-02 | 2013-12-02 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法 |
CN201410659325.0A CN104387333B (zh) | 2013-12-02 | 2014-11-19 | 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1,2,4‑三唑‑3‑基硫基)乙酸钠的晶型及其制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710060519.2A Division CN106883190A (zh) | 2013-12-02 | 2014-11-19 | 雷西纳得的钠盐的晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104387333A CN104387333A (zh) | 2015-03-04 |
CN104387333B true CN104387333B (zh) | 2018-04-17 |
Family
ID=50164282
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310633354.5A Pending CN103613552A (zh) | 2013-11-22 | 2013-12-02 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法 |
CN201410659325.0A Expired - Fee Related CN104387333B (zh) | 2013-11-22 | 2014-11-19 | 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1,2,4‑三唑‑3‑基硫基)乙酸钠的晶型及其制备方法 |
CN201710060519.2A Pending CN106883190A (zh) | 2013-12-02 | 2014-11-19 | 雷西纳得的钠盐的晶型及其制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310633354.5A Pending CN103613552A (zh) | 2013-11-22 | 2013-12-02 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710060519.2A Pending CN106883190A (zh) | 2013-12-02 | 2014-11-19 | 雷西纳得的钠盐的晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN103613552A (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015075561A2 (en) * | 2013-11-22 | 2015-05-28 | Crystal Pharmatech Co., Ltd. | Crystalline forms of lesinurad and its sodium salt |
CN107337649B (zh) * | 2016-04-29 | 2020-10-16 | 四川科伦药物研究院有限公司 | 一种乙酸钠水合物无定型及其制备方法和用途 |
WO2019001325A1 (zh) * | 2017-06-28 | 2019-01-03 | 苏州科睿思制药有限公司 | 雷西纳得的晶型xv及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101918377A (zh) * | 2007-11-27 | 2010-12-15 | 亚德生化公司 | 新颖化合物和组合物以及使用方法 |
CN102741234A (zh) * | 2010-01-08 | 2012-10-17 | 亚德生化公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的多晶型、结晶型及中间相型与其用途 |
CN103298796A (zh) * | 2010-12-30 | 2013-09-11 | 阿迪亚生命科学公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的多晶型形式及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
SI2582683T1 (en) * | 2010-06-15 | 2018-07-31 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricaemia |
CN103249417A (zh) * | 2010-10-15 | 2013-08-14 | 阿迪亚生命科学公司 | 用于治疗高尿酸血症及相关疾病的方法 |
-
2013
- 2013-12-02 CN CN201310633354.5A patent/CN103613552A/zh active Pending
-
2014
- 2014-11-19 CN CN201410659325.0A patent/CN104387333B/zh not_active Expired - Fee Related
- 2014-11-19 CN CN201710060519.2A patent/CN106883190A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101918377A (zh) * | 2007-11-27 | 2010-12-15 | 亚德生化公司 | 新颖化合物和组合物以及使用方法 |
CN102741234A (zh) * | 2010-01-08 | 2012-10-17 | 亚德生化公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的多晶型、结晶型及中间相型与其用途 |
CN103298796A (zh) * | 2010-12-30 | 2013-09-11 | 阿迪亚生命科学公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的多晶型形式及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103613552A (zh) | 2014-03-05 |
CN104387333A (zh) | 2015-03-04 |
CN106883190A (zh) | 2017-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102382075B (zh) | 3-[5-(2-氟苯基)-[1,2,4]噁二唑-3-基]-苯甲酸的晶型 | |
WO2016184436A1 (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
CN106008521A (zh) | 依鲁替尼的新晶型及其制备方法 | |
CN104387333B (zh) | 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1,2,4‑三唑‑3‑基硫基)乙酸钠的晶型及其制备方法 | |
CN110494423A (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
CN104447590B (zh) | 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1,2,4‑三唑‑3‑基硫基)乙酸的晶型及其制备方法 | |
JP2018501289A (ja) | ネラチニブマレイン酸塩の新規な結晶形及びその製造方法 | |
JP5730986B2 (ja) | プラスグレル塩の結晶性形態 | |
CN104529919B (zh) | 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1,2,4‑三唑‑3‑基硫基)乙酸的共晶及其制备方法 | |
EP3256474B1 (en) | Ibrutinib sulphate salt | |
WO2023040513A1 (zh) | Amg510化合物的晶型及其制备方法和用途 | |
WO2019228485A1 (zh) | 一种甲磺酸乐伐替尼新晶型及其制备方法 | |
CN105061420B (zh) | 一种jak抑制剂的晶型及其制备方法和应用 | |
WO2011092664A1 (en) | Crystalline forms of l-malic acid salt of sunitinib | |
CN110156793A (zh) | 瑞博西尼单琥珀酸盐新晶型及制备方法 | |
JP2013540810A (ja) | 1−{(2S)−2−アミノ−4−[2,4−ビス(トリフルオロメチル)−5,8−ジヒドロピリド[3,4−d]ピリミジン−7(6H)−イル]−4−オキソブチル}−5,5−ジフルオロピペリジン−2−オン酒石酸塩の水和物 | |
JP2023548293A (ja) | 2-ヒドロキシ-6-((2-(1-イソプロピル-1h-ピラゾール-5-イル)ピリジン-3-イル)メトキシ)ベンズアルデヒドの調製のための方法 | |
WO2017028802A1 (zh) | 5-[2, 6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺二盐酸盐的晶型及其制备方法 | |
CN106831620A (zh) | 雷西纳得的晶型及其制备方法 | |
WO2020048299A1 (zh) | 药物共晶体及其制备方法 | |
JP2018508581A (ja) | アセチルサリチル酸誘導体の結晶及びその調製方法と用途 | |
CN110964017A (zh) | 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途 | |
CN106794179A (zh) | 马赛替尼甲磺酸盐的新晶型及其制备方法 | |
WO2016101912A1 (zh) | 一种表皮生长因子受体激酶抑制剂的盐的晶型及其制备方法 | |
WO2023221122A1 (en) | Salts and solid forms of an estrogen receptor antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 215123 Biological Park B4-10, No. 218 Xing Hu Street, Suzhou Industrial Park, Jiangsu Co-patentee after: SUZHOU PENGXU PHARMATECH Co.,Ltd. Patentee after: CRYSTAL PHARMATECH Co.,Ltd. Address before: 215123 Biological Park B4-10, No. 218 Xing Hu Street, Suzhou Industrial Park, Jiangsu Co-patentee before: SUZHOU PENGXU PHARMATECH Co.,Ltd. Patentee before: Crystal Pharmatech Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180417 Termination date: 20211119 |